Drugs /

tesetaxel

Back to Drugs List

Overview

NCI Definition [1]:
A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and stabilizes tubulin, promoting microtubule assembly and thereby preventing microtubule depolymerization. This may lead to cell cycle arrest and an inhibition of cell proliferation. This agent may also inhibit pro-angiogenic factors such as vascular endothelial growth factor (VEGF). As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors.

Clinical Trials

View Clinical Trials for tesetaxel

Tesetaxel has been investigated in 5 clinical trials, of which 1 is open and 4 are closed. Of the trials investigating tesetaxel, 1 is phase 1 (0 open), 3 are phase 2 (1 open), and 1 is phase 3 (0 open).

HER2 Deficient Expression, HER2 Negative, and ER Expression are the most frequent biomarker inclusion criteria for tesetaxel clinical trials.

Breast carcinoma and solid neoplasm are the most common diseases being investigated in tesetaxel clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tesetaxel
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tesetaxel
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tesetaxel and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tesetaxel, dj-927, dj927, dj 927, oral taxane derivative dj-927
NCIT ID [1]:
C37451

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.